Dianalitics
ANI Pharmaceuticals, Inc.
ANIP · v3 · 2026-09-04
arrow_back
homeHomemonitoringPerformancesearch
hourglass
Loading…
Preparing the latest DD data, styles and content.
67OpportunityDD: Sep 04, 2026Analyst: 77
paidPrice at analysis date
USD 72.0 (04/09/2026)
domainMkt cap
$1.54B
pie_chartShares
21.43M
candlestick_chart52W
$70.15-$99.50
trending_downShort interest
16.21%
INFONASDAQHealth Care970 employeesFounded 2001
Verdict: Favorable Risk/Reward

ANI is a profitable specialty-pharma compounder: Cortrophin is scaling fast, generics provide cash flow, and leverage is moving in the right direction. The discount looks excessive if FY2026 guidance is met, but the position deserves a concentration haircut because Cortrophin now drives the thesis.

📊 DIANALITICS RESEARCH INDEX
Company & Thesis AssessmentScore /100 - updated 2026-09-04
77
ANI Pharmaceuticals (ANIP)
Health Care - Specialty pharmaceuticals
"Profitable rare-disease growth at a discounted multiple"
FY26E revenue $1.11B midpointAdj. EBITDA $292.5M midpointShort interest 16-17% floatCortrophin concentration
Fin. strength
16
/20 pts
EBITDA/FCF
14
/15 pts
Debt/leverage
11
/15 pts
Stage/business
14
/15 pts
Catalysts
7
/10 pts
Reg. risk
5
/8 pts
Risk/reward
4
/7 pts
Management
3
/5 pts
Sector/macro
1
/3 pts
Compliance
2
/2 pts
Fair value estimate - sum-of-the-parts EV bridge
Fair value base case
USD 107.0
Range: USD 79.0-USD 128.0
Price at analysis date: USD 72.0 (04/09/2026)
Base upside/downside: +49%

The SoTP base case translates to roughly 8.8x FY2026E adjusted EBITDA. A cross-check using 10.6x FY2026E adjusted EPS midpoint of $9.44 gives about $100 per share, while the visible analyst average is $108.38; the internal $107 estimate sits between those two anchors. Sensitivity is material: every 1.0x change in FY2026E adjusted EBITDA multiple moves equity value by about $13.51 per share. The bear case mainly reflects concentration and policy risk, not balance-sheet distress. Not investment advice.

ComponentAssumptionUSD/share
Cortrophin Gel franchise$530M FY2026E revenue midpoint x 3.2x EV/Sales = $1,696M / 21.65M diluted shares+78.34
ILUVIEN retina franchise$80.5M FY2026E revenue midpoint x 2.0x EV/Sales = $161M / 21.65M diluted shares+7.44
Generics and Other$410M FY2026E residual revenue x 1.2x EV/Sales = $492M / 21.65M diluted shares+22.73
Brands, royalties and Harmony$89.5M FY2026E residual revenue x 2.5x EV/Sales = $224M / 21.65M diluted shares+10.34
CG Oncology appeal option20% probability x $250M royalty-claim option value = $50M / 21.65M diluted shares+2.31
Net debt bridge($376.96M cash/investments - $626.03M debt) / 21.65M diluted shares-11.50
Dilution and governance reserve2.5% per-share haircut on $109.66 pre-reserve value for share creep and insider-sale overhang-2.66
FV base case78.34 + 7.44 + 22.73 + 10.34 + 2.31 - 11.50 - 2.66$107.00
Bull
$128
Probability: 25%
Cortrophin gout expansion works, ILUVIEN stabilizes, repurchases begin and the market applies about 10.3x FY2026E adjusted EBITDA.
Base
$107
Probability: 50%
ANI hits guidance, Cortrophin grows 50%-55%, free cash flow reduces net debt and the stock rerates toward 8.8x FY2026E adjusted EBITDA.
Bear
$79
Probability: 25%
Cortrophin slows, payer scrutiny rises, generics price erosion accelerates and the multiple stays close to 6.7x FY2026E adjusted EBITDA.
Methodology: The SoTP base case translates to roughly 8.8x FY2026E adjusted EBITDA. A cross-check using 10.6x FY2026E adjusted EPS midpoint of $9.44 gives about $100 per share, while the visible analyst average is $108.38; the internal $107 estimate sits between those two anchors. Sensitivity is material: every 1.0x change in FY2026E adjusted EBITDA multiple moves equity value by about $13.51 per share. The bear case mainly reflects concentration and policy risk, not balance-sheet distress. Not investment advice. Not investment advice.
warning
Watch item - Cortrophin guidance reset and insider-sale overhang
Cortrophin guidance was trimmed to $520M-$540M even though growth remains strong, while May-July 2026 insider sales add a governance optics issue. The stock is not a fragile story, but it is not a clean low-risk compounder either.
check_circle
Record Q2 and visible September investor catalyst cluster
Q2 2026 revenue reached $266.0M (+25.9% YoY), adjusted EBITDA was $71.6M (+32.4% YoY), operating cash flow was $115.0M year to date, and management reaffirmed FY2026 revenue guidance of $1.08B-$1.14B with adjusted EBITDA of $285M-$300M.
Methodology note: ANIP is not a pre-approval biotech. It is already profitable, has positive free cash flow and reports formal FY2026 guidance. The fair value therefore uses a sum-of-the-parts EV bridge with EV/Sales checks by franchise and an EV/Adjusted EBITDA sanity check, rather than a clinical rNPV model.
Capital Structure - Short Interest - Repurchase & Dilution
Short Interest
16-17%
MarketBeat reported 3.42M shares short at Aug. 14, 2026, equal to 16.21% of float and 7.4 days to cover. StockAnalysis shows a similar 17.41% of float.
Net debt
~$249M
Cash and investments of about $377M versus total debt of about $626M leave leverage manageable, especially against $285M-$300M FY2026E adjusted EBITDA.
Repurchase authorization
$100M
The board authorized a program through May 2029, but the Q2 2026 10-Q showed no open-market repurchases under the plan during Q2.
Short Interest - context
ANIP - 16%-17% of float
High

The short base is high enough to make Q3 results and Cortrophin commentary important. Insider activity also matters: CEO Nikhil Lalwani sold about $4.27M of stock on May 11, 2026, and director Patrick Walsh sold roughly $1.13M across May 11-13, 2026. Those sales do not break the thesis, but they reduce the cleanliness of the setup.

$Financial analysis - FY 2026E
Q2 revenue
$266.0M
+25.9% YoY
Q2 adj. EBITDA
$71.6M
+32.4% YoY
FY26E revenue guide
$1.11B
midpoint, +22%-29%
TTM free cash flow
$173.0M
17.7% FCF margin
ItemFY2023FY2024FY2025TTM Jun. 2026FY2026E / Guide
Revenue$486.8M$614.4M$883.4M$978.4M$1.08B-$1.14B
Adjusted EBITDA$134.0M$156.0M$229.8M~$259.6M run-rate TTM$285M-$300M
Net income$15.5M-$20.2M$70.2M-$77.2M$99.6Mpositive
Operating cash flow$119.0M$64.0M$185.2M$189.5Mpositive and debt-reducing
Net debt$64.6M$472.9M$333.6M$249.1Mdeclining if FCF holds
Adjusted EBITDA is company-defined non-GAAP. The FY2025 net-income range reflects release and data-provider presentation differences; the trend is what matters: profitability and cash generation have improved sharply since the Alimera integration.
Quarterly dynamics - last 5 quarters
MetricQ2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Revenue ($M)211.4227.8247.1237.5266.0
Rare Disease revenue ($M)104.0N/DN/D94.4135.8
Adjusted EBITDA ($M)54.159.665.463.071.6
Net income ($M)8.5N/D27.529.524.7
Cash ($M)217.8262.6285.6311.2360.2
Financial position and sustainability
Net debt / FY26E adj. EBITDA
~0.85x
Current EV / FY26E adj. EBITDA
~6.1x
account_tree

Business model - rare disease plus generics cash engine

Competitive advantage: commercial execution in niche pharmaceuticals
ANI's model combines a high-growth rare-disease franchise, a broad generic launch engine, mature brands and royalty economics. Cortrophin is the value driver, but the generics base and cash generation make the business less binary than a single-asset biotech.

Cortrophin Gel $520M-$540M FY2026E core growth engine Guided to 50%-55% growth. The gout sales force was fully operational by late June, and management cited record new cases in July. ILUVIEN / retina $78M-$83M FY2026E integration asset Q2 declined 16.1% due to international shipment timing. Detailed SYNCHRONICITY data are expected at a Q4 2026 medical conference. Generics and Other ~$410M FY2026E cash engine Q2 generics revenue was $99.1M, up 9.7% YoY. ANI launched 12 generics year to date and targets at least 15 in 2026. Brands and royalties ~$90M FY2026E margin support Harmony economics added $15M upfront in Q1 and $17.7M in Q2 brand royalties and other revenue, including an $8M development milestone.

gavel

Legal, regulatory and risk analysis

Cortrophin concentration
High
Cortrophin is the central value driver. A growth slowdown, reimbursement issue or competitive pressure would hit both EBITDA and the multiple.
Payer and policy exposure
High
Specialty-drug pricing, access management and government reimbursement changes can pressure rare-disease economics even when prescription demand is healthy.
Leverage and convertible notes
Moderate
Debt is manageable versus EBITDA, but absolute debt is still material. Continued cash generation is needed to keep the deleveraging narrative intact.
Short interest
High
A 16%-17% short float can amplify volatility around guidance, Cortrophin commentary and analyst revisions.
Insider-sale overhang
Moderate
Large insider sales in May 2026 create optics risk, especially while the stock trades below consensus targets.
Generic price erosion
Moderate
The generics engine is useful, but the category remains exposed to competition, price compression and supply interruptions.
Execution quality
Positive
Record Q2 revenue, improving cash, multiple generic launches and reaffirmed guidance show strong operating execution.
CG Oncology appeal option
Positive
ANI is appealing Delaware rulings tied to assets sold to CG Oncology and seeks economics from cretostimogene. This is upside optionality, not core value.
account_tree

SWOT and decision framework

Strengths
  • +Record revenue and EBITDA, formal FY2026 guidance, positive free cash flow.
  • +Cortrophin has strong growth and a larger gout-focused field force.
  • +Net debt is falling and the repurchase authorization creates optional capital return.
Weaknesses
  • −Value is increasingly concentrated in Cortrophin.
  • −Diluted share count and insider-sale optics dilute the quality signal.
  • −ILUVIEN timing volatility makes the retina franchise harder to model quarter to quarter.
Opportunities
  • →Q3/Q4 results can prove that lowered Cortrophin guidance is conservative.
  • →SYNCHRONICITY data and Harmony milestones can add non-Cortrophin narrative support.
  • →A short base above 16% of float can accelerate rerating after clean execution.
Threats
  • !Pricing or access pressure in specialty pharma.
  • !Generic erosion offsets rare-disease growth.
  • !Debt, dilution and insider transactions keep valuation below peer averages.
Why it works
The market price of $71.99 implies roughly 6.1x FY2026E adjusted EBITDA, too low if ANIP hits guidance and converts EBITDA to cash.
What can break it
Cortrophin is the fulcrum. Any sign that the growth curve or reimbursement environment is weakening would justify a lower multiple.
What to watch next
September conferences, Q3 2026 earnings, ILUVIEN Q4 medical data, and whether the repurchase authorization becomes active.
Sources & Disclaimer

Sources: ANI Pharmaceuticals Q2 2026 results release and SEC exhibit dated Aug. 7, 2026; ANI Q1 2026 results release; ANI FY2025 results release and 2025 Form 10-K; ANI Q2 2026 Form 10-Q; ANI investor events page; ANI CG Oncology appeal release dated Jul. 16, 2026; StockAnalysis price, financials, statistics and analyst-forecast pages checked Sep. 4, 2026; MarketBeat ANIP chart and short-interest pages checked Sep. 4, 2026; Finviz insider transaction table checked Sep. 4, 2026; SEC Form 4 filings. Market data - last verified close 2026-09-03: ANIP ~$71.99, market cap ~$1.54B, 52W range $70.15-$99.50, 21.43M shares outstanding. Short interest: 3.42M shares, 16.21% of float, 7.4 days to cover. Additional context: enterprise value about $1.79B; total debt about $626M and cash/investments about $377M. This document is for informational purposes only and does not constitute financial or investment advice.